ABSTRACT
Prion diseases or transmissible spongiform encephalopathies are neurodegenerative disorders that are genetic, sporadic, or infectious. The pathogenetic event common to all prion disorders is a change in conformation of the cellular prion protein (PrP C ) to the scrapie isoform (PrP Sc ), which, unlike PrP C , aggregates easily and is partially resistant to protease digestion. Although PrP Sc is believed to be essential for the pathogenesis and transmission of prion disorders, the mechanism by which PrP Sc deposits cause neurodegeneration is unclear. It has been proposed that in some cases of prion disorders, a transmembrane form of PrP, termed Ctm PrP may be the mediator of neurodegenerative changes rather than PrP Sc per se. In order to understand the underlying cellular processes by which PrP Sc mediates neurodegeneration, we have investigated the mechanism of neurotoxicity by a β-sheet rich peptide of PrP in a cell model. We show that exposure of human neuronal cell lines NT-2 and M17 to the prion peptide 106-126 (PrP ) catalyzes the aggregation of endogenous cellular prion protein (PrP C ) to an amyloidogenic form that shares several characteristics with
PrP
Sc . Intracellular accumulation of these PrP Sc -like forms upregulates the synthesis of Ctm PrP, which is proteolytically cleaved in the endoplasmic reticulum and the truncated Cterminal fragment is transported to the cell surface. In addition, we have isolated mutant NT-2 and neuroblastoma cells that are resistant to toxicity by PrP to facilitate further characterization of the biochemical pathways of PrP 106-126 neurotoxicity. The PrP -resistant phenotype of these cells could result from aberrant binding or internalization of the peptide, or due to an abnormality in the downstream pathway(s) of neuronal toxicity. Thus, our data suggest that PrP Sc aggregation occurs by a process of 'nucleation' on a pre-existing 'seed' of PrP. Furthermore, the PrP -resistant cells reported here will provide a unique opportunity for identifying the cellular and biochemical pathways that mediate neurotoxicity by PrP Sc .
INTRODUCTION
Prion disorders occur when a normally expressed surface glycoprotein, the prion protein (PrP C ), changes its conformation from a predominantly α-helical to a β-sheet rich form that is pathogenic (PrP Sc ). This transformation is caused by an exogenous source of PrP Sc in infectious disorders, is triggered by prion protein gene mutations in the inherited forms, and is believed to be a random, spontaneous event the case of sporadic disorders. After the initial conversion, subsequent conversion of additional PrPC molecules occurs spontaneously, resulting in PrPSc deposits in the brain parenchyma. PrP Sc differs from PrP C in several biophysical characteristics, such as increased aggregability and resistance to protease digestion. Amyloid deposits comprised of PrP Sc are one of the principal causes of neuronal toxicity in prion disorders (1) (2) (3) (4) 106-126 is rich in β-sheet structure, forms aggregates that are detergent insoluble and PK-resistant, and is toxic to primary cultures of neurons (10) (11) (12) . Furthermore, residues 90-141 of PrP are sufficient for initiating or blocking the transformation of PrP C , probably because this is the principal site of PrP Sc and PrP C binding during the conversion process (13) (14) (15) (16) . This region can be further narrowed down to residues 112-120, which are considered particularly important for the binding and inhibitory effect (12, 15) . Using this peptide, several PrP binding proteins have been identified on neuronal cells, including glial fibrillary acidic protein (GFAP), Bcl-2, a 66kDa membrane protein, and the 37kDa laminin receptor precursor protein (17, 18) . Recently, PrP has been shown to interact with α-and β-tubulin, with the suggestion that the toxic effects of this fragment are mediated by altering intracellular calcium homeostasis (44 PrP as an important mediator of prion-related neuropathology. In addition, the PrP 106-126 -resistant neuronal cells described in this report will provide an important experimental tool for identifying the specific biochemical pathways that mediate toxicity by PrP , and by extrapolation, PrP Sc . . Anti-PrP monoclonal antibody 8H4 that binds to a site between residues 145-180 of PrP was raised in our facility (19) . All other chemicals were purchased from Sigma. PrP C -expressing human neuroblastoma cells were generated as described previously (20) , and cultured in the presence of 500µg/ml of hygromycin B. NT-2 cells expressing high levels of PrP were isolated by repeated sub-cloning of cells obtained from ATCC.
MATERIALS AND METHODS

Materials and cell culture conditions
Mutagenesis and selection of PrP106-126 resistant cells
The following peptides were custom-synthesized for the selection of PrP First, PrP C -expressing neuroblastoma (M17) and NT-2 cells were immunostained with anti-PrP antibody 3F4 and sorted by FACS analysis to select cells expressing high levels of PrP. These cells were expanded in culture and mutagenized by either ethyl-methyl-sulfonate (EMS, 150µg/ml) or N-methyl-N'-nitro-N-nitrosoguanidine (MNNG, 10 µg/ml). After culturing for 24 hours in the presence of these mutagens, the cells were washed and cultured in regular medium for 1 week. Cultures showing 50% cell death after exposure to mutagens were grown in culture for one week to allow recovery from mutageninduced toxicity, and exposed to PrP 106-126 , PrP (80µM), or only solvent. The peptide-containing medium was changed every third day. Cell death was monitored by lactate dehydrogenase (LDH) assay of the culture medium every 24 hours. The cytotoxicity assay kit CytoTox96 was used for measuring LDH activity according to the manufacturer's instructions. Every week, the cells were trypsinized, re-plated, and supplemented with the peptides. Non-mutagenized M17 and NT-2 cells received a similar treatment, and were used as controls. Parallel cultures were exposed to biotin-PrP 106-126 and biotin-PrP , and the cells were stained with Texas-red conjugated Streptavidin at different time points till the control, non-mutagenized cells finally died at ~6 weeks. In the initial two weeks of treatment, the cells treated with PrP 106-126 in fact proliferated. With continued treatment, the intracellular deposits of PrP 106-126 became larger, and the LDH activity released in the medium continued to increase. The number of apoptotic cells in the culture were determined by Hoechst staining (1 µg/ml dye; Molecular probes) and Tunnel assay (Oncor, Gaithersburg, MD) performed on a small aliquot of cells cultured separately on coverslips, according to the manufacturer's instructions. In short, MTT was added to the wells to a final concentration of 1 mg/ml, and incubated at 37 o C for 3 hours. Cells were lysed with 20% SDS solution of 50% dimethylformamide, pH 4.7, incubated overnight at 37 o C, and MTT reduction was determined colorimetrically at an OD of 550 nm. After six weeks of treatment with PrP 106-126 , almost all of the non-mutagenized cells treated with PrP 106-126 died. Among the mutagenized cells, ~2% of the cells treated with PrP 106-126 survived, which started forming colonies. There was no effect on control or mutagenized cells treated with PrP Scm106-126 , or the solvent alone. In fact PrP Scm106-126 could not be detected on the cell surface or in any intracellular compartment throughout the six weeks of treatment.
In a parallel set of dishes, non-mutagenized, NT-2 cells expressing high amounts of PrP C or PrP C -transfected neuroblastoma cells were cultured in the presence of nontoxic concentrations of PrP 106-126 (5µM), or the scrambled peptide for 1-12 months. At the time of sub-culture, biotintagged PrP 106-126 or biotin-tagged PrP Scr106-126 (5µM) was dissolved in culture medium, centrifuged at 1000g for 10 minutes to eliminate large aggregates, and the supernatant was added to the cells. Every three days, the cells were trypsinized and sub-cultured with fresh peptide solution.
Immunofluorescence staining and confocal microscopy
For all immunostaining experiments, anti-PrP antibody 8H4 was used for detecting cellular PrP. This antibody is specific to residues 145-180 of PrP, and thus does not react with PrP . For detecting PrP or PrP , streptavidin-conjugated-Texas red was used due to the specific binding of streptavidin with biotin. For immunostaining cell surface proteins, permeabilization of the membrane with Triton X-100 was omitted. NT-2 cells cultured in normal medium, or 5 µM of PrP 106-126 or PrP were fixed and stained with 8H4 (1:25)-antimouse-FITC (1:25) (Southern Biotechnology Associates), followed by streptavidin-conjugated-Texas red (1:40) (Pierce). For intracellular staining, fixed cells were permeabilized with 0.1% Triton X-100 prior to immunostaining as above. Stained cells were incubated with Hoechst 33342 (1µg/ml) (Molecular Probes) for five minutes to detect apoptotic nuclei, and mounted in gelmount (Biomeda Corp., Fostar City, CA). All samples were observed with a Laser Scanning Confocal Microscope (BioRad MRC 600). A single 5µm optical section, and a composite of several sections were evaluated in each case.
Electron microscopy
For immunoelectron microscopy, control and PrP 106-126 -treated cells were fixed in 4% paraformaldehyde and 0.01% glutaraldehyde, and immunostained with 8H4 (1:20 dilution), followed by peroxidase-conjugated antimouse (1:50) and mouse PAP (1:250). After washing with PBS, the cells were exposed to 3,3'-diaminobenzidine (DAB) containing 0.1M imidazole to obtain an electrondense reaction product, and fixed again with 2.5% glutaraldehyde. Subsequently, the cells were post-fixed in 1% osmium tetroxide, dehydrated, embedded in Epon 812, and processed for electron microscopy. Post-staining with uranyl acetate and lead citrate was omitted to enhance the contrast for PrP-specific DAB stain. For intracellular immunostaining, fixed cells were permeabilized with 0.1% Triton X-100 before processing as above. For ultrastructural analysis, cells were fixed directly in the culture dish with a freshly prepared solution of 2.5% glutaraldehyde and post-fixed with 1% osmium tetroxide. Samples were rinsed in distilled water, block-stained in 0.5% uranyl acetate, dehydrated, and embedded in Epon as above. Thin sections were stained with uranyl acetate and lead citrate before examination with a Zeiss electron microscope (Zeiss CEM 902; Carl Zeiss Inc., Thornwood, NY).
SDS-PAGE and Western Blotting
Control and PrP 106-126 -treated NT-2 cells were processed for Western blotting as described (22) . In short, cells were lysed, and the precipitated proteins were electrophoretically transferred to Immobilon-P (Millipore) for 2.5 hours at 70 volts at 4 o C. Membranes containing transferred proteins were probed with either anti-PrP antibody 8H4 (1:1000) followed by anti-mouse-HRP (1:4000), or streptavidin-conjugated HRP (1:40,000).
Reactive bands were visualized on an autoradiographic film by ECL (Amersham).
Metabolic labeling and immunoprecipitation
Control and peptide-treated cells were radiolabeled with 50µCi/ml of Trans 35 S-label overnight in DMEM containing 5% dialyzed serum. The cells were washed with PBS, and incubated with 1µl/ml of PI-PLC (Oxford Glycosystems) in Opti-MEM for 1 hour at 37 o C. PI-PLC-released proteins in the medium, and cell lysates were subjected to immunoprecipitation with the anti-PrP antibody 3F4 or 8H4 as described (22, 23) . 3F4 binds to residues 109 and 112 of PrP that are included in the truncated Ctm PrP and the conventional PK-resistant 20kDa fragment of PrP, and helps to distinguish these fragments from the 18kDa C-terminal fragment that is a product of normal PrP processing in the endosomes (24) . Anti-PrP antibodies 8H4 and 2301 bind to both 18 and 20kDa fragments.
Assay of detergent insolubility and proteinase-K resistance
Aggregation, insolubility in non-ionic detergents, and partial resistance to proteinase K (PK) digestion are the hallmarks of PrP Sc . To assay detergent insolubility, control, or peptide treated cells were lysed in a buffer containing non-ionic detergents NP-40 (1%) and DOC (0.5%). Large aggregates and nuclei were pelleted by low speed centrifugation at 500g, and the low-speed supernatant was further ultra-centrifuged at 100,000g in a Beckman SW50 rotor for 1 hour at 4 o C. The low and high-speed pellet and supernatant samples were analyzed by Western blotting. Duplicate sets of samples were electroblotted, and probed with 8H4 or streptavidin-HRP as above. Only the low speed fraction is shown here.
For evaluation of PK-resistance, lysates of control and PrP 106-126 treated cells were exposed to 3µg/ml of PK for 0, 2, or 4 minutes at 37 o C. The reaction was stopped with 1mM PMSF, and proteins were electroblotted and probed with 3F4 as described (20) .
Cell homogenization and PK-treatment
Control and peptide-treated cells were washed and homogenized on ice in a buffer containing 10mM HEPES (pH7.9), 1.5mM MgCl 2 , 10mM KCl, and 0.5mM DTT by 10 strokes of a Kontes all glass Dounce homogenizer.
The homogenate was checked microscopically for cell breakage and centrifuged to pellet nuclei. The resulting supernatant was centrifuged at 20,000g to pellet membrane vesicles. These were resuspended in 0.5ml of transport buffer (25mM HEPES pH7.4, 115mM KoAc, 2.5mM MgCl 2 , 10mM KCl, 2.5mM CaCl 2 , and 1mM DTT), and treated with 20µg/ml of proteinase-K on ice for 30 minutes. After adding 5mM of PMSF to stop the reaction, membrane vesicles were pelleted, solubilized in lysis buffer, and immunoblotted with 3F4.
Staining with Thioflavin S
Untreated control, and cells treated with PrP (Figure 1, panel 4) , whereas control cells show only a small amount of PrP immunoreactivity in the Golgi area (Figure 1, panel 3) .
These results were confirmed by immunoelectron microscopy. Cells were fixed, permeabilized, and immunostained with 8H4. The bound antibody was reacted with appropriate secondary antibody and diaminobenzidine (DAB) to obtain an electron-dense deposit. Subsequent staining with uranyl acetate and lead citrate was omitted to obtain a better contrast with DAB staining. Cells cultured with scrambled peptide show a uniform distribution of PrP (Figure 1, panel 6 ).
These results show that exogenously added PrP 106-126 induces the aggregation and internalization of cell surface PrP C in large membrane-bound vesicles. These aggregates degrade slowly, and persist even after one week of chase in normal medium (data not shown). 
Aggregates of PrP C are insoluble in non-ionic detergents
Insolubility in non-ionic detergents is one of the earliest changes observed during the transition of PrP C to PrP Sc . Conventionally, this is determined by preparing cell lysates in a buffer containing NP40 (1%) and DOC (0.5%), and subjecting lysates clarified at low speed to ultracentrifugation at 100,000g. Aggregated PrP is detected in the pellet fraction of ultracentrifuged samples. To check if the PrP C deposits observed in Figure 1 are aggregated, control and treated cells cultured in the presence of PrP 106-126 for 1-12 months were subjected to the above treatment, and the pellet and supernatant fractions from low and highspeed centrifugation were immunoblotted with streptavidin or 8H4 to detect PrP 106-126 or PrP C respectively. Only the low speed lysate obtained after centrifugation at 500g is shown in Figure 2 , since almost all of the aggregated PrP from peptide-treated cells partitions in this fraction. PrP C is soluble in non-ionic detergents, and is therefore also detected in the low speed fraction (Figure 2, lanes 3 and 4) . In contrast, most of the PrP 106-126 and aggregated PrP C from peptide treated cells is detected in the stacking gel of this fraction ( Figure 2, lanes 2 and 4, top arrows) . PrP-reactive protein aggregates in peptide-treated cells are too large to be resolved by the stacking or the separating gel, and crossreact with streptavidin, indicating that these are complex aggregates of PrP 
Internalized PrP 106-126 and PrP C aggregates bind the amyloid-specific dye Thioflavin-S
To evaluate if intracellular aggregates of PrP 106-126 and PrP C acquire the characteristics of amyloid, M17 and NT-2 cells treated with PrP 106-126 for 1 year were fixed with paraformaldehyde, permeabilized with detergent, and stained with the basic dye hematoxylin, followed by the amyloid binding dye thioflavin-S. Green fluorescence of thioflavin-stained aggregates can be seen in intracellular structures (Figure 3, panels 1 and 2) , similar to the large endocytic vesicles observed in Figure 1 above. Coimmunostaining with 8H4 followed by RITC-conjugated secondary antibody shows that most of the thioflavinpositive aggregates co-immunostain for PrP C (data not shown, 25). Thus, intracellular aggregates of PrP C and PrP 106-126 acquire some of the characteristics of amyloid. PrP is inserted in the ER membrane through its hydrophobic domain consisting of residues 113-135, with its N-terminus in the cytosol and C-terminus in the ER lumen. Thus, proteinase K (PK) treatment of microsomes spares ~19kDa C-terminal fragment, which is significantly increased in brain tissue obtained from diseased animals (8) . To determine whether the 20kDa fragment observed in peptide treated cells is the proteolytically cleaved Ctm PrP, microsomes prepared from peptide-treated neuroblastoma cells were treated with 20µg/ml of PK on ice for 30 minutes. The reaction was stopped with PMSF, and the microsomes were solubilized in detergent and subjected to immunoblotting with 3F4. As expected, full-length GPIlinked forms of PrP C are protected from the protease PrP is spontaneously cleaved on the cytosolic face of the ER membrane to release the C-terminal 20kDa fragment, which is transported to the plasma membrane.
A C-terminal 20kDa fragment of
Isolation of PrP
106-126 -resistant mutants To dissect the biochemical pathways of neurotoxicity by PrP , mutant cells that are resistant to toxicity by this peptide were isolated. Neuroblastoma and NT-2 cells were chosen for these experiments.
Neuroblastoma cells express high amounts of PrP and are easy to expand and maintain in culture, and NT-2 cells, a human teratocarcinoma cell line has the advantage that it can be differentiated into mature human neurons (NT-2N) by a series of treatments with retinoic acid, and mimics primary human neuronal cultures closely (42) . After full differentiation, NT-2N cells still express detectable amounts of PrP, and ~95% of the cells stain positive for the neuronal marker NF68. Before proceeding with the selection of resistant cells, we confirmed that the differentiated NT-2N cells are as sensitive to PrP treatment as undifferentiated NT-2 cells.
To isolate resistant cells, neuroblastoma and NT-2 cells were exposed to the mutagens MNNG or EMS, and the dose that killed ~50% of the cells were chosen for further selection. Cells exposed to the mutagens were cultured in regular medium for one week to obtain healthy cultures. Subsequently, mutagenized, and non-mutagenized control cells were exposed to the constant presence of 80µM of PrP or PrP Scm106-126 in complete medium for a period of 3-4 weeks. Cell-death was monitored by checking lactate-dehydrogenase (LDH) activity released into the medium. During the first week of treatment, LDH released into the medium continued to rise in control (NT-2), and NT-2 mutagenized with MNNG or EMS. Subsequently, LDH values continued to rise in NT-2 cells till all the cells died after 5-6 weeks. In mutagenized cells, the LDH values started to decrease after one week, and were virtually similar to untreated samples at the end of six weeks. The mutant cells that survived PrP 106-126 treatment were expanded in the constant presence of the peptide. PrP 106-126 -resistant neuroblastoma cells were selected in a similar fashion, and checked by re-exposing to toxic doses of the peptide. As shown in Figure 5 , although the cells are engorged with large aggregates of PrP , the cell viability is not compromised, as assessed by nuclear staining with the chromatin binding dye Hoechst ( Figure 5 , panels 2 and 3).
Preliminary characterization of PrP 106-126 -resistant cells
To check for differences in the expression of any major cellular proteins in the resistant cells, control and resistant cells were labeled with 35 S-methionine/cysteine for 2 hours, lysed with detergent, and the radiolabeled proteins precipitated by cold methanol were analyzed by SDS-PAGE-fluorography. Only a minor quantitative difference in the protein band migrating at ~18kDa is detected between the control and PrP 106-126 -resistant NT-2 cells mutagenized with EMS (NT-2ER) or MNNG (NT-2MR) ( Figure 6, lanes 1-3) . No detectable differences were noticed in resistant neuroblastoma cells (data not shown). An analysis of the difference in mRNA pattern between the control and mutant cells by differential display analysis is under way.
To assess for any differences in the uptake and intracellular distribution of PrP 106-126 by the resistant cells, PrP 106-126 -resistant NT-2 cells were exposed to biotinylated PrP 106-126 for 10 days, and stained with texas-redconjugated streptavidin. The resistant cells show a variety of distribution patterns of PrP106-126. Some cells fail to internalize the peptide, which is seen at the cell surface ( Figure  7 , panels 1 and 2). Others have large intracellular aggregates of PrP106-126 without any apparent toxic effects on the cell (Figure 7, panels 3 and 4) . Although several cells show large intracellular aggregates, no nuclear fragmentation was detected when stained with the chromatin-binding dye Hoechst (data not shown). These cells are presently being cloned in order to evaluate the specific biochemical changes that confer PrP106-126-resistance to these cells.
DISCUSSION
This study broadens our understanding of the possible mechanisms of PrP replication and PrP Sc -induced neurotoxicity in significant ways. First, we show that a β- By exposing cultured NT-2 and neuroblastoma cells to non-toxic concentrations of PrP106-126, we demonstrate a change in conformation of endogenous PrPC into a PrPSc-like form. While the cellular and biochemical processes that mediate neuronal toxicity by PrPSc are still unclear, substantial evidence indicates that propagation of PrPSc occurs through the conversion of host PrPC into its own conformation. Two hypotheses have been proposed to explain the mechanism of this conformational change: 1) template-assisted re-folding of endogenous PrPC to PrPSc, and 2) the nucleation or seeding hypothesis (26, 27). We show that a ?-sheet-rich internal fragment PrP106-126 seeds the aggregation of PrPC on the plasma membrane, and catalyzes its accumulation in an exponential manner. We believe that PrP106-126 incorporates within the lipid bilayer, where the charged phospholipid environment induces its aggregation. Subsequently, it acts as a seed for the deposition of additional PrPC molecules. Since ?-sheet rich peptides have an affinity for cholesterol (10, 28) , aggregated PrP106-126 probably concentrates in cholesterolrich lipid domains of the plasma membrane, which is also the sub cellular location for the conversion of PrPC to PrPSc (29) (30) (31) , thus providing an ideal environment for the conversion to PrPSc.
After the initial conformational change, PrP C and PrP aggregates are transported to the endosomal/lysosomal compartment, where low pH and the negatively charged membrane microenvironment probably plays a major role in promoting their transformation to thioflavin-S-binding, ?-sheet rich, amyloidogenic structures. The accumulation of these virtually undegradable PrP C and PrP 106-126 aggregates explains the extensive proliferation of lysosomes observed in our cell model (25) , and the presence of abundant PrP immunoreactive lysosomes in the neurons of scrapie-infected animals and New Variant Creutzfeldt Jakob Disease patients (29, 32) . A similar change in conformation from an α-helical to a β-sheet structure has been reported for recombinant PrP 91-231 and for certain other peptides when exposed to an acidic pH (1, 33) .
The intracellular aggregates of PrP
C generated in our model display the essential biochemical characteristics of PrP Sc , including detergent insolubility, and partial resistance to digestion by proteinase K (PK) (25) . In fact, most of the aggregated PrP C is insoluble even in SDS, and cannot be resolved by conventional SDS-PAGE. It is plausible that these aggregates travel along axons to neighboring cells by vesicular traffic, or alternately, are extruded into the extracellular milieu and are subsequently internalized by other cells. Microglia cultured in the presence of Aβ show similar results (34 causes neuronal death by apoptosis when added to primary cultures of neurons (35) (36) (37) . Although the biochemical events mediating neurotoxicity by this fragment are not clear, the region encompassing residues 112-126 is believed to be essential for the neurotoxic effect of this peptide (38) . A similar phenomenon of neurotoxicity is observed when neuronal cells are exposed to PrP Sc (39, 40 (15, 41) . Residues 113-120 seem to be especially critical for this inhibitory effect, and the inhibition of conversion is independent of the peptide's ability to form β-sheets. PrP peptides including residues 90-145 have been shown to induce aggregation, high β-sheet content, and PKresistance in PrP C in vitro (13) , and PrP109-122 can induce the transition from α-helix to β-sheets in other PrP peptides (14) . Additional evidence for the critical role of this region of PrP in the conversion of PrP C to PrP Sc is derived from the fact that mutant mouse PrP lacking residues 114-121 is not converted to the scrapie form after expression in scrapie infected mouse neuroblastoma cells (16) . Thus, PrP closely parallels cellular events that follow the exposure of PrP Sc to neuronal cells. By isolating cell clones resistant to toxicity by this peptide, we will be able to identify specific biochemical pathways mediating the neurotoxicity of PrP Sc . We chose the human neuroblastoma M17 transfected with PrP, and NTera-2 (NT-2), a human teratocarcinoma cell line that can be differentiated into mature human neurons for isolating PrP -resistant cells (42) . M17 cells are easy to maintain in culture and large quantities can be obtained in a short time, whereas NT-2 cells offer the opportunity of analyzing a pure population of mature human neurons. Since primary brain cultures are usually a mixture of nerve cells and glial populations, this cell system offers several advantages over existing methods used to analyze the toxicity of PrP106-126. Undifferentiated NT-2 cells can be grown in culture with relative ease, and upon differentiation with retinoic acid, are a constant source of ~95-100% pure culture of mature human neurons (42) . Therefore, mutagenesis and several of the preliminary experiments can be performed on NT-2 cells, and then confirmed in differentiated cells (NT-2N). Biochemical and genetic studies are also more feasible in NT-2 or NT-2N cells than primary cultures of central nervous system neurons, which are difficult to obtain in large quantities, and are heavily contaminated with other cells. Moreover, NT-2N cells can be engrafted in the brains of nude mice, where they can survive for several months Our results show that PrP 106-126 is internalized by M17 and NT-2 cells in a time and temperature-dependant fashion. On the cell surface, it does not appear to bind PrP, confirming earlier studies that the uptake of this peptide is not affected in PrP-deficient cells (44) . However, contrary to a previous report (21) , our results show that PrP accumulates in the lysosomes, where it is relatively stable and forms large aggregates. After a prolonged exposure of the cells to PrP , it can also be detected in axon-like processes of both cells lines. Whether this is due to endocytosis of the peptide by axons or represents transport of the peptide from one cell to the next is not clear from our data. Transport of PrP Sc through axons in scrapie-infected brains has been reported in earlier studies (45) .
The PrP -resistant cell clones isolated in this study will help to clarify several outstanding questions, such as the role of oxidative damage, probably induced by activated microglia (37) , the interaction of α-and β-tubulin with PrP 106-126 (44) , and the importance of plasma membrane microviscosity and intracellular calcium levels in the toxicity mediated by this peptide (46, 47) . Some of the PrP -resistant cells do not internalize the peptide, and may lack the receptor involved in the internalization of this peptide, whereas others contain large intracellular aggregates of this peptide with apparently no toxic effect on the cells. These cells probably differ from PrP 106-126 -sensitive control cells in the biochemical pathway(s) mediating neurotoxicity by this peptide. We are presently carrying out complementation studies with different clones to identify the biochemical abnormalities that confer the resistant phenotype to these cells. We believe that an analysis of these clones will help to characterize the cellular and biochemical pathways that lead to cell death by PrP 106-126 , and will provide insight into the mechanism of neurotoxicity by PrP Sc .
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